Argenica Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Argenica Therapeutics has a total shareholder equity of A$14.0M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$16.4M and A$2.4M respectively.

Key information

Debt to equity ratio

AU$0

Debt

Interest coverage ratio	n/a
Cash	AU$15.91m
Equity	AU$13.95m
Total liabilities	AU$2.43m
Total assets	AU$16.38m

Recent financial health updates

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Sep 23

Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Jan 12

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Aug 12

Recent updates

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Sep 23

Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Jan 12

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Jul 20

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Apr 20

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Nov 30

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Aug 12

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Apr 29

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Dec 30

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Sep 16

Financial Position Analysis

Short Term Liabilities: AGN's short term assets (A$16.4M) exceed its short term liabilities (A$2.4M).

Long Term Liabilities: AGN has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: AGN is debt free.

Reducing Debt: AGN has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AGN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: AGN has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 35.6% each year.

Argenica Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Key information

Recent financial health updates

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Recent updates

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Less than half of directors are independent

Argenica Therapeutics Limited, Annual General Meeting, Nov 12, 2024

Argenica Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 12 million.

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Argenica Therapeutics Limited Announces Changes to its Board, Effective 1 December 2023

Argenica Therapeutics Limited, Annual General Meeting, Nov 30, 2023

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Argenica Therapeutics Limited Announces Preclinical Data Shows ARG-007 Inhibits A Cause of Alzheimers

Argenica Therapeutics Limited Announces Successful Completion of Phase 1 Clinical Trial Dosing

Argenica Therapeutics Limited Announces Successful Completion of Phase 1 Clinical Trial Dosing

Argenica Therapeutics Limited Approves Commencement of Fourth and Final Cohort Dosing

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Argenica Therapeutics Limited Announces That the First Subjects in the Third Cohort of Its Phase 1 Clinical Trial of ARG-007 Have Been Dosed

Argenica Therapeutics Limited Announces the Approval by the Phase 1 Safety Review Committee (SRC) to Progress to the Third Escalated Dose Cohort

Less than half of directors are independent

Argenica Therapeutics Limited Announces Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial

Argenica Therapeutics Limited Announces the Approval by the Phase 1 Safety Review Committee to Progress to the Second Escalated Dose Cohort

Argenica Therapeutics Limited Announces Healthy Participants in the First Cohort of Its Phase 1 Clinical Trial of ARG-007 Have Been Successfully Dosed, Indicating Good Safety and Tolerability of ARG-007 in These Participants

Argenica Therapeutics Limited Announces First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007

Argenica Therapeutics Limited Announces Further Positive Preclinical Results for ARG-007 in Hypoxic-Ischaemic Encephalopathy

Argenica Therapeutics Limited, Annual General Meeting, Nov 24, 2022

Argenica Therapeutics Limited Announces Phase 1 Clinical Trial Summary

Argenica Therapeutics Limited Receives Ethics Approval to Commence Phase 1 Trial

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Argenica Therapeutics Limited Submits Application to Seek Approval to Commence Phase 1 Healthy Participant Study of ARG-007

Argenica Therapeutics Limited Appoints Dr. Jeffery Saver to Clinical Advisory Committee

Argenica Therapeutics Limited Announces Completion of the Final Pharmacokinetic (PK) Study of ARG-007 Required for the Phase 1 Clinical Trial

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Argenica Therapeutics Limited Announces Results of In-Life Rodent and Non-Human Primate Toxicology Studies Which Have Established the Maximum Tolerated Dose (MTD) of ARG-007

Less than half of directors are independent

Less than half of directors are independent

Argenica Therapeutics Limited Announces Management Changes

Argenica Therapeutics Limited Announces Positive Preclincal Data on Efficacy of ARG-007

Argenica Therapeutics Limited Announces Successful Completion of Final GLP Genotoxicity Studies

Argenica Therapeutics Announces Completion of Preliminary Pre-Clinical Tox Studies

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Argenica Therapeutics Limited Provides Additional Information of Study Shows ARG-007 Does Not Degrade

Argenica Therapeutics Limited Provides Positive Preliminary for ARG-007

Argenica Therapeutics Limited Completes Pilot Pre-Clinical Pharmacokinetics Study

Argenica Therapeutics Limited has completed an IPO in the amount of AUD 7 million.

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Cash Runway Analysis

Discover healthy companies